OPKO Health (NASDAQ:OPK) Posts Earnings Results, Misses Expectations By $0.03 EPS

OPKO Health (NASDAQ:OPK) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.03), Briefing.com reports. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The business had revenue of $173.70 million for the quarter, compared to the consensus estimate of $182.99 million. During the same period in the prior year, the business posted ($0.02) EPS. OPKO Health’s quarterly revenue was down 26.9% on a year-over-year basis.

OPKO Health Trading Up 0.8 %

Shares of OPK opened at $1.26 on Friday. OPKO Health has a fifty-two week low of $0.85 and a fifty-two week high of $2.24. The firm has a market cap of $878.21 million, a price-to-earnings ratio of -5.04 and a beta of 1.81. The firm has a 50 day moving average price of $1.15 and a 200-day moving average price of $1.22. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.22 and a current ratio of 1.55.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Wednesday. StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Friday, March 1st. Piper Sandler reaffirmed an “overweight” rating and set a $5.00 price objective on shares of OPKO Health in a report on Monday, April 1st. Finally, Barrington Research reissued an “outperform” rating and issued a $1.50 target price on shares of OPKO Health in a research note on Monday, April 1st.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the stock in a transaction on Wednesday, February 28th. The stock was acquired at an average cost of $0.99 per share, with a total value of $495,000.00. Following the completion of the purchase, the chief executive officer now directly owns 208,868,225 shares of the company’s stock, valued at approximately $206,779,542.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have acquired 3,100,000 shares of company stock valued at $2,923,000. Insiders own 47.26% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.